Navidea Biopharmaceuticals, Inc. (NAVB)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 13.93 Million USD | 10.64% |
| 2021 | 12.59 Million USD | 8.32% |
| 2020 | 11.62 Million USD | 5.85% |
| 2019 | 10.98 Million USD | -0.82% |
| 2018 | 11.07 Million USD | -29.4% |
| 2017 | 15.68 Million USD | -28.37% |
| 2016 | 21.89 Million USD | -27.12% |
| 2015 | 30.04 Million USD | -7.04% |
| 2014 | 32.32 Million USD | -17.62% |
| 2013 | 39.23 Million USD | 39.79% |
| 2012 | 28.06 Million USD | 13.63% |
| 2011 | 24.7 Million USD | 78.94% |
| 2010 | 13.8 Million USD | 68.18% |
| 2009 | 8.2 Million USD | 3.66% |
| 2008 | 7.91 Million USD | -80.8% |
| 2007 | 41.23 Million USD | 499.36% |
| 2006 | 6.87 Million USD | -4.29% |
| 2005 | 7.18 Million USD | 28.19% |
| 2004 | 5.6 Million USD | 12.22% |
| 2003 | 4.99 Million USD | -10.64% |
| 2002 | 5.59 Million USD | 109.73% |
| 2001 | 2.66 Million USD | -22.35% |
| 2000 | 3.43 Million USD | -65.91% |
| 1999 | 10.07 Million USD | -69.38% |
| 1998 | 32.89 Million USD | 6.75% |
| 1997 | 30.81 Million USD | 29.29% |
| 1996 | 23.83 Million USD | 100.31% |
| 1995 | 11.9 Million USD | -5.56% |
| 1994 | 12.6 Million USD | 425.0% |
| 1993 | 2.4 Million USD | -20.0% |
| 1992 | 3 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q2 | 2.42 Million USD | 0.22% |
| 2023 Q1 | 2.42 Million USD | -23.07% |
| 2023 Q3 | 2.13 Million USD | -12.21% |
| 2022 Q3 | 4.82 Million USD | 64.71% |
| 2022 Q4 | 3.14 Million USD | -34.72% |
| 2022 FY | 13.93 Million USD | 10.64% |
| 2022 Q1 | 2.97 Million USD | -19.25% |
| 2022 Q2 | 2.92 Million USD | -1.7% |
| 2021 Q3 | 2.51 Million USD | -14.08% |
| 2021 Q4 | 3.68 Million USD | 46.52% |
| 2021 Q2 | 2.93 Million USD | -15.14% |
| 2021 FY | 12.59 Million USD | 8.32% |
| 2021 Q1 | 3.45 Million USD | 14.36% |
| 2020 Q4 | 3.01 Million USD | 3.94% |
| 2020 FY | 11.62 Million USD | 5.85% |
| 2020 Q1 | 2.68 Million USD | -3.2% |
| 2020 Q2 | 2.34 Million USD | -12.54% |
| 2020 Q3 | 2.9 Million USD | 23.67% |
| 2019 Q1 | 2.52 Million USD | 14.06% |
| 2019 FY | 10.98 Million USD | -0.82% |
| 2019 Q4 | 2.77 Million USD | -10.18% |
| 2019 Q3 | 3.08 Million USD | 14.92% |
| 2019 Q2 | 2.68 Million USD | 6.46% |
| 2018 FY | 11.07 Million USD | -29.4% |
| 2018 Q4 | 2.21 Million USD | -40.25% |
| 2018 Q3 | 3.7 Million USD | 39.59% |
| 2018 Q2 | 2.65 Million USD | 6.19% |
| 2018 Q1 | 2.49 Million USD | -36.09% |
| 2017 Q3 | 2.6 Million USD | -52.0% |
| 2017 Q4 | 3.91 Million USD | 49.9% |
| 2017 Q2 | 5.43 Million USD | 45.81% |
| 2017 FY | 15.68 Million USD | -28.37% |
| 2017 Q1 | 3.72 Million USD | -32.34% |
| 2016 Q2 | 5.41 Million USD | -19.87% |
| 2016 FY | 21.89 Million USD | -27.12% |
| 2016 Q4 | 5.5 Million USD | 30.65% |
| 2016 Q3 | 4.21 Million USD | -22.11% |
| 2016 Q1 | 6.75 Million USD | 5.91% |
| 2015 FY | 30.04 Million USD | -7.04% |
| 2015 Q4 | 6.37 Million USD | -18.69% |
| 2015 Q2 | 6.34 Million USD | -33.03% |
| 2015 Q3 | 7.84 Million USD | 23.62% |
| 2015 Q1 | 9.47 Million USD | 48.99% |
| 2014 Q3 | 6.8 Million USD | -32.09% |
| 2014 Q2 | 10.01 Million USD | 9.65% |
| 2014 FY | 32.32 Million USD | -17.62% |
| 2014 Q1 | 9.13 Million USD | -31.99% |
| 2014 Q4 | 6.35 Million USD | -6.54% |
| 2013 FY | 39.23 Million USD | 39.79% |
| 2013 Q4 | 13.43 Million USD | 31.09% |
| 2013 Q2 | 8.54 Million USD | 22.02% |
| 2013 Q3 | 10.24 Million USD | 19.93% |
| 2013 Q1 | 7 Million USD | -0.41% |
| 2012 FY | 28.06 Million USD | 13.63% |
| 2012 Q4 | 7.03 Million USD | -22.45% |
| 2012 Q3 | 9.06 Million USD | 66.5% |
| 2012 Q2 | 5.44 Million USD | -16.44% |
| 2012 Q1 | 6.51 Million USD | -27.92% |
| 2011 Q2 | 4.37 Million USD | -21.35% |
| 2011 FY | 24.7 Million USD | 78.94% |
| 2011 Q4 | 9.04 Million USD | 34.39% |
| 2011 Q3 | 6.72 Million USD | 53.88% |
| 2011 Q1 | 5.55 Million USD | 50.51% |
| 2010 Q2 | 2.65 Million USD | -24.76% |
| 2010 Q3 | 3.92 Million USD | 47.8% |
| 2010 Q4 | 3.69 Million USD | -5.89% |
| 2010 FY | 13.8 Million USD | 68.18% |
| 2010 Q1 | 3.52 Million USD | 71.34% |
| 2009 FY | 8.2 Million USD | 3.66% |
| 2009 Q4 | 2.06 Million USD | 3.87% |
| 2009 Q2 | 2.17 Million USD | 1.57% |
| 2009 Q3 | 1.98 Million USD | -8.75% |
| 2009 Q1 | 2.14 Million USD | 4.25% |
| 2008 Q3 | 2.62 Million USD | 45.55% |
| 2008 Q2 | 1.8 Million USD | 25.26% |
| 2008 Q1 | 1.43 Million USD | -96.09% |
| 2008 Q4 | 2.05 Million USD | -21.76% |
| 2008 FY | 7.91 Million USD | -80.8% |
| 2007 FY | 41.23 Million USD | 499.36% |
| 2007 Q4 | 36.82 Million USD | 2872.74% |
| 2007 Q3 | 1.23 Million USD | -18.81% |
| 2007 Q2 | 1.52 Million USD | -7.34% |
| 2007 Q1 | 1.64 Million USD | -13.49% |
| 2006 Q1 | 1.68 Million USD | -5.58% |
| 2006 FY | 6.87 Million USD | -4.29% |
| 2006 Q3 | 1.89 Million USD | 35.59% |
| 2006 Q2 | 1.39 Million USD | -17.21% |
| 2006 Q4 | 1.9 Million USD | 0.52% |
| 2005 FY | 7.18 Million USD | 28.19% |
| 2005 Q2 | 2.13 Million USD | 44.53% |
| 2005 Q4 | 1.78 Million USD | -0.49% |
| 2005 Q3 | 1.79 Million USD | -15.76% |
| 2005 Q1 | 1.47 Million USD | -0.27% |
| 2004 Q1 | 1.39 Million USD | -0.26% |
| 2004 Q2 | 1.44 Million USD | 3.68% |
| 2004 Q3 | 1.28 Million USD | -11.33% |
| 2004 Q4 | 1.47 Million USD | 15.17% |
| 2004 FY | 5.6 Million USD | 12.22% |
| 2003 Q1 | 1.17 Million USD | -13.03% |
| 2003 FY | 4.99 Million USD | -10.64% |
| 2003 Q4 | 1.4 Million USD | 10.78% |
| 2003 Q3 | 1.26 Million USD | 9.01% |
| 2003 Q2 | 1.15 Million USD | -1.15% |
| 2002 Q2 | 1.44 Million USD | 2.01% |
| 2002 Q1 | 1.41 Million USD | 85.64% |
| 2002 FY | 5.59 Million USD | 109.73% |
| 2002 Q4 | 1.34 Million USD | -2.62% |
| 2002 Q3 | 1.38 Million USD | -4.03% |
| 2001 Q3 | 569.06 Thousand USD | -17.47% |
| 2001 FY | 2.66 Million USD | -22.35% |
| 2001 Q2 | 689.51 Thousand USD | 6.99% |
| 2001 Q1 | 644.48 Thousand USD | -35.42% |
| 2001 Q4 | 761.99 Thousand USD | 33.9% |
| 2000 Q4 | 997.96 Thousand USD | 51.21% |
| 2000 Q2 | 701.95 Thousand USD | -34.6% |
| 2000 Q1 | 1.07 Million USD | -41.99% |
| 2000 FY | 3.43 Million USD | -65.91% |
| 2000 Q3 | 659.99 Thousand USD | -5.98% |
| 1999 Q3 | 2.78 Million USD | 20.87% |
| 1999 Q2 | 2.3 Million USD | -14.81% |
| 1999 Q4 | 1.85 Million USD | -33.45% |
| 1999 Q1 | 2.7 Million USD | -80.14% |
| 1999 FY | 10.07 Million USD | -69.38% |
| 1998 Q4 | 13.59 Million USD | 171.94% |
| 1998 Q1 | 7.9 Million USD | -16.99% |
| 1998 FY | 32.89 Million USD | 6.75% |
| 1998 Q2 | 6.3 Million USD | -20.25% |
| 1998 Q3 | 5 Million USD | -20.63% |
| 1997 Q2 | 8.6 Million USD | 43.33% |
| 1997 Q4 | 9.51 Million USD | 44.19% |
| 1997 Q3 | 6.6 Million USD | -23.26% |
| 1997 FY | 30.81 Million USD | 29.29% |
| 1997 Q1 | 6 Million USD | -23.43% |
| 1996 FY | 23.83 Million USD | 100.31% |
| 1996 Q4 | 7.83 Million USD | 11.95% |
| 1996 Q3 | 7 Million USD | 27.27% |
| 1996 Q2 | 5.5 Million USD | 37.5% |
| 1996 Q1 | 4 Million USD | 14.29% |
| 1995 Q3 | 2.9 Million USD | 3.57% |
| 1995 Q4 | 3.5 Million USD | 20.69% |
| 1995 FY | 11.9 Million USD | -5.56% |
| 1995 Q2 | 2.8 Million USD | -6.67% |
| 1995 Q1 | 3 Million USD | -34.78% |
| 1994 FY | 12.6 Million USD | 425.0% |
| 1994 Q1 | 1 Million USD | 129.41% |
| 1994 Q2 | 800 Thousand USD | -20.0% |
| 1994 Q3 | 3 Million USD | 275.0% |
| 1994 Q4 | 4.6 Million USD | 53.33% |
| 1993 Q4 | -3.4 Million USD | -247.83% |
| 1993 Q2 | 2.1 Million USD | 50.0% |
| 1993 Q3 | 2.3 Million USD | 9.52% |
| 1993 FY | 2.4 Million USD | -20.0% |
| 1993 Q1 | 1.4 Million USD | 27.27% |
| 1992 FY | 3 Million USD | 0.0% |
| 1992 Q3 | 900 Thousand USD | 0.0% |
| 1992 Q4 | 1.1 Million USD | 22.22% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 32.07 Million USD | 56.567% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -50.319% |
| Armata Pharmaceuticals, Inc. | 11.64 Million USD | -19.595% |
| Actinium Pharmaceuticals, Inc. | 52 Million USD | 73.209% |
| Azitra, Inc. | 8.3 Million USD | -67.802% |
| Can-Fite BioPharma Ltd. | 8.93 Million USD | -55.869% |
| Chromocell Therapeutics Corporation | 6.86 Million USD | -103.017% |
| Calidi Biotherapeutics, Inc. | 28.99 Million USD | 51.947% |
| CEL-SCI Corporation | 31.47 Million USD | 55.739% |
| iBio, Inc. | 16.85 Million USD | 17.364% |
| Lineage Cell Therapeutics, Inc. | 33 Million USD | 57.792% |
| MAIA Biotechnology, Inc. | 20.18 Million USD | 30.971% |
| Matinas BioPharma Holdings, Inc. | 24.86 Million USD | 43.964% |
| NovaBay Pharmaceuticals, Inc. | 12.89 Million USD | -8.014% |
| NanoViricides, Inc. | 8.51 Million USD | -63.591% |
| Oragenics, Inc. | 5.45 Million USD | -155.534% |
| BiomX Inc. | 26.81 Million USD | 48.044% |
| BiomX Inc. | 26.81 Million USD | 48.044% |
| Protalix BioTherapeutics, Inc. | 32.05 Million USD | 56.534% |
| Palatin Technologies, Inc. | 34.67 Million USD | 59.817% |
| Scorpius Holdings, Inc. | 39.81 Million USD | 65.01% |